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ABSTRACT
The Schlafen family of proteins was first characterized in 19881, and since then evidence of their
relevance in different physiological and pathological situations have been accumulating although
at a slow pace. Hence, the biological roles of these proteins remain ill-defined. The expression of
these proteins is positively regulated by type 1 interferons, constituting a component of the innate
immune response. Functions of these proteins vary from regulation of cell proliferation to
restriction of viral infections. Recent studies have implicated SLFN11 and SLFN13 as inhibitors
of HIV-1 infection2-4. The mechanism of action of SLFN11 resides in its capacity to regulate the
size of the host tRNA pool, thus counteracting changes in the tRNA repertoire induced by viral
infections2,4. However, no relevant cellular models of HIV-1 infection were used to asses this
information. Moreover, only one additional report has confirmed the original observations made
seven years ago. This situation has fueled doubts in the HIV-1 research community regarding the
relevance of SLFN11 anti-HIV-1 mechanism. Importantly, in this work we have validated the
tRNase-dependent anti-HIV-1 activity of SLFN11 in human CD4+ T cells and cells of myeloid
origin, the main targets of HIV-1 in vivo. Furthermore, we revealed a novel tRNase-independent
anti-HIV-1 activity in murine SLFN proteins. These are important contributions to the anti-viral
innate immune response field, and they could be exploited in HIV-1 cure strategies.
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INTRODUCTION
HIV, Epidemic and Statistics. The first HIV case was reported in 1981, and since then no cure
has been found. HIV-1 infection is still one of the most sexually transmitted diseases worldwide.
Back in 2012, 35.3 million people were living with HIV in Southern Africa, representing 70.8%
worldwide. Statistics show that globally, 37.9 million people were living with HIV in 2018. Out
of the 37.09 million people infected with HIV, 18.8 million accounts for infection in women, and
17.4 million in men. Around 1.7 million are children of 15 years or less. 23.3 million were
receiving anti-retroviral treatments by the end of 2018 5. However, 770 000 HIV- related deaths
were reported in 2018, from where 670,000 occurred in adults, and 100,000 in children. These
finding suggests a decrease in mortality compared to the number of HIV related deaths in 2000
(1.4 million people) and a 56% decrease in the number of people dying from HIV causes in 2004,
when the highest peak of infection was registered

6,7 .

The reduction of mortality is associated to

the acquirement and access of antiretroviral therapy in the past years.
HIV Pathogenesis. HIV is a lentivirus that belongs to the family of retroviruses, it has a spherical
structure of around 120 nm, and it is composed of two identical positive- sense single stranded
RNA molecules of about 9200 nucleotides. These RNA molecules are enclosed within a capsid
and a viral envelope. The viral envelope consists of two glycoproteins: gp120 and gp41. The
interaction of the viral glycoprotein gp120 with the cell surface receptor CD4 and a co- receptor
(CXCR4) or (CCR5) allows for a conformational change in which the N- terminal of the
transmembrane protein gp41due to its hydrophobic nature inserts itself into the host cell membrane
forming a channel, bringing the mature HIV particle in closer proximity to the host cell until fusion
of the membranes is achieved. The viral capsid is translocated into the cytoplasm of the target cell,
and viral RNA is released. Encoded in the viral RNA is the enzyme reverse transcriptase whose
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function consists in the transcription of the single stranded RNA into complementary DNA
(cDNA). A host tRNA (Lys3) used as a primer by RT8. Reverse transcriptase binds to the primer
binding site, this is around 180 nucleotides from the 5′ of the genomic RNA 9. As viral RNA is
being transcribed as single-stranded cDNA, the RNA-DNA complex previously formed is
degraded by the RNAse activity of RT. The DNA- dependent DNA polymerase activity of RT
converts the single-stranded cDNA into double stranded DNA10. After DNA synthesis is
completed, a pre-integration complex (PIC) is created, consisting of the protein integrase (IN), the
viral protein R (Vpr), the matrix protein (MA), as well as the dsDNA and the protein reverse
transcriptase11. Integrase carries the double stranded DNA, while Vpr plays an important role in
nuclear transport. DNA is transported into the nucleus through the nucelar pores, however, due to
the size of the PIC complex, a nuclear localization signal (NLS) is required. These NLS signals
have been found in the proteins of the PIC (IN,MA and Vpr)12. Studies have demonstrated that the
NLS signals present in MA introduce a positive charge crucial for nuclear targeting
properties11.Vpr is a multifunctional protein necessary for successful infection of CD4 cells, but it
is also crucial for nuclear transport. Studies have shown that the interaction of Vpr with importin
alpha targets the PIC to the nucleus, which promotes binding to nuclear pore proteins 13. Other
functions of the vpr protein include cell cycle arrest and and activation of HIV-1 LTR
transcription13. Integrase (IN) has two necessary catalytic functions to successfully replicate HIV1: Transport of dsDNA to the nucleus and transfer into the host DNA. Integrase binds to the double
stranded DNA in a dimer manner to each end of the strand. Integrase then traverses a nuclear pore,
thus accessing to the nucleus of the host cell. A transcriptional coactivator (LEDGF/p75) assists
integrase serving as a tethering factor between integrase and chromatin thus promoting integration
to the target sequence on the host genome11,14. Once transportation to the nucleus is achieved,
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cleavage of the 3′ end of viral DNA is catalyzed. In this reaction known as 3′ processing, GT
dinucleotides are removed, leaving a 5′ flanking at the end of the viral genome, called sticky ends.
Another important reaction, strand transfer takes place when integrase attacks the 3′ hydroxyl
groups at ends of the viral DNA on phosphodiester bonds in the host DNA15. After integration of
the viral DNA into the host genome, repair of the gaps created in this process are repaired by
cellular enzymes16. Once the viral DNA is integrated into the host DNA the infection is persistent,
and this newly synthesized DNA is known as proviral DNA. Proviral DNA is flanked by long
terminal repeats (LTR’s) at both ends in which the promotor for transcription is encoded. Long
terminal repeats are subsequently divided in 3 regions: U3, R and U5. Located 28 bp upstream of
the transcription start site in the U3 region is the HIV-1 TATA box. The R region contains the
TAR hairpin, which serves as the binding site of TAT, a trans-activator protein of HIV-1 that
increases virus production by approximately 100-fold17,18. Adjacent to the 5′ LTR is the gag gene,
encoding for the structural proteins p24, p17, p7 and p6. Then, the pol reading frame follows,
encoding for the enzymes protease (p10), RNase H (p15) and reverse transcriptase (p51). Adjacent
to the pol gene is the env reading frame, encoding for the envelope glycoproteins gp120 and gp41.
The transactivator protein (p14) is enconded in the tat gene, followed by nef gene encoding for
p19, an RNA splicing regulator. These proteins are said to be required for HIV-1 replication since
they regulate gene transcription. The negative regulating factor (p27) encoded by nef is responsible
for downregulation on CD4 cells, thus preventing the super infection of those. In addition, it has
been demonstrated that nef enhances pathogenicity in vivo and is required for the progression of
the infection19. Followed by the nef gene is the vif gene encoding for the viral infectivity protein
(p23) that enhances the production of infectious virus. The regulatory proteins Vpr (p15) and Vpu
(p16) have an influence in the rate of the production of viral particles20-22. Proteolytic cleavage of
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precursor proteins (p55 and p160) takes place at the end of the budding process, in which the lipid
envelop of the virion is acquired. Attachment of HIV to a target cell (CD4) varies between 30
minutes and 2 hours, and after 6 hours transcription is completed. Integration is also achieved in
the following 6 hours and finally, 24 hours after infection viral particles are released 23.
HIV-1 Latency. Latent infection is the main obstacle for curing HIV-1 infection. Upon integration
HIV-1 infection can be eliminated only by eliminating the infected cells. However, latently
infected cells cannot be eradicated by the cytopathic effects of the virus, the host immune system
or anti-retroviral drugs because latently infected cells do not express viral proteins. Latency is
achieved when the proviral genome is replicated with and as part of the host cell genome without
viral protein expression23. However, once latency is established in a CD4 memory cell it will have
the ability to escape from the host immune response and even from highly active antiretroviral
therapy (HAART)

24.

The primary reservoir for HIV-1 latent proviruses are naïve CD4 T cells,

which exists in a resting state, until they are activated after encountering antigens. Subsequently,
some of these cells persist as memory T cells, and will respond to the same antigen in future
infections25. Induction of transcription factors such as NFAT and NF- Κ by cytokines or antigens
promote the activation of HIV-1 proviruses 25. Molecular mechanisms of HIV-1 latency include
transcriptional interference, insufficient levels of transcriptional activators, presence of
transcriptional repressors, insufficient TAT activity, nucleosome positioning among others26.
Moreover, research has shown that stability of HIV-1 latency is attributed to cpG methylation of
the HIV-1 5′ LTR, a mechanism that promotes resistance to reactivation signals24
HIV Proteins are codon biased. The interaction between host and pathogen has been remarkably
studied to understand how adaptive genetic changes affect fitness of species. Molecular resources
on the host are exploited by pathogens to assure survival and growth, meanwhile the host fight to
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eliminate such pathogen. Virulence, ability to hide within the host and infectivity are the main
factors that pathogens maximize to maintain replicative fitness27. Humans have acquired complex
mechanisms of defense to attack and eliminate pathogens. In contrast, pathogens developed the
ability to mutate, thus evading the host immune response. It is known that the human code is
degenerated, due to the fact that 64 codons encode for 20 amino acids, meaning that multiple
codons code for a specific amino acid. Frequency of usage of synonymous codons, also called
codon bias is exhibited in most organisms, and they contribute to mutation- selection balance27.
Synonymous mutations do not change the primary sequence of the protein; however it changes the
base composition of genes. In fact, it has been demonstrated that enriched genes for the preferred
codons have higher translational efficiency. Precisely, some bacteriophage genes have been
enriched in the codons preferred by their bacterial host. However, not all pathogen-host
associations and codon usage are defined in the same way. A number of RNA viruses display low
association with their host in codon usage and base composition 27. The study of the codon usage
pattern between HIV-1 and its host has been used as a suitable model to understand the pathogen
genome evolution in such interaction. It is known that in coding regions, the human genome is
GC- rich. In contrast, HIV-1 has an A- rich genome. Codon usage pattern of 9 HIV-1 genes were
compared in respect to its host, results demonstrate that the rev, tat and nef genes are closest to
humans, and that env, gag and pol as well as vif and vpu cluster away from humans27. Furthermore,
relative neutrality plots for HIV-1 and general human genes show that all HIV-1 genes have more
than 50% of their preferentially used codons as A/T ending, indicating extreme bias 27. This means,
that the codons rarely used by the host are used by the HIV-1 late expressing genes, this is env,
gag, pol, vif and vpu. In contrast, rev, tat and nef, the early expressing genes of HIV-1 showed less
preference for A/T ending codons27. Increased usage of human preferred codons in these three
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HIV-1 genes suggest a role in translation selection, which explains how HIV-1 has developed an
strategy to evade restrictions based in codon usage, such as Slfn11. I will describe this innate
immune antiviral strategy below.
The Schlafen Family of Proteins, Classification and Characterization. The Schlafen family of
proteins was first characterized by David A. Schwarz and its research group in 1988 at the
University of California at San Diego when they identified 4 mouse SLFNs: mSLFN1, mSLFN2,
mSLFN3 and mSLFN4. Further studies lead to the classification of other mouse and human
schlafen genes based on their size and function (Fig. 1).10 SLFN proteins have been identified in
mice: mSLFN1, mSLFN1L, mSLFN2, mSLFN3, mSLFN4, mSLFN5, mSLFN8, mSLFN9,
mSLFN10 and mSLFN 1428,29; whereas that only 5 in humans: SLFN5, SLFN11, SLFN12,
SLFN13, and SLFN1430. These proteins have been classified in groups based on their structural
characteristics.

Group I SLFNs include proteins with molecular masses between 37 to 42 kDa. mSLFN1,
mSLFN1L, and mSLFN2 correspond to this group, which like all SLFN genes, they contain a slfn
box that lies under an AAA domain30,31. Group II consists of mSLFN3, mSLFN4 and SLFN12,
whose molecular masses range between 58 to 68 kDa 30. One of the most important features of this
group is the presence of a specific domain called SWADL, which is defined by the amino acid
sequence (Ser-Trp-Ala-Asp-Leu)29,31. The largest SLFNs belong to group III, whose molecular
masses are between 100 to 104 kDa. In addition to the slfn box, the SWADL domain and the AAA
6

domain, this group preserves a C- terminal domain homologous to the DNA/ RNA helicases32,
which suggests that these proteins have a function in the nucleus 33. mSLFN5, mSLFN8, mSLFN9,
mSLFN10, mSLFN14, SLFN5, SLFN11, SLFN13 and SLFN14 belongs to this group.
Regulation of SLFN proteins Expression. Previous research has shown that human IFN type 1
receptors are involved in the induction of SLFN genes, some of these genes include SLFN5,
SLFN11, SLFN12 and SLFN1334. mSLFN protein expression is also induced by interferons.
Specifically, when mouse cells are treated with IFNα, mRNA expression of SLFN1, SLFN2,
SLFN5 and SLFN8 is highly induced 34. Stat 1, and Stat 3 proteins were required for the induction
of mSLFN genes, suggesting that mSLFN gene induction occurs in the same manner as classic
interferon-stimulated genes34,35. However, neither Stat 3 nor p38 MAPK were required for
mSLFN 5, suggesting that another mechanism of regulation might be followed34. In the other hand,
activation of T cells significantly downregulate SLFN genes. Activation of T lymphocytes with
anti-CD3 or a combination of CD28 or CD3 antibodies exhibit downregulation of most SLFN
genes. SLFN 5 was downregulated gradually, while SLFN12 was downregulated by 50% 6 hours
after T cell activation. Expression of SLFN12 and SLFN11 was not altered36. . The expression of
SLFN2 is upregulated when mouse macrophages are treated with LPS and unmethylated CpG
dinucleotides (CpG-DNA) by activating the NF-kB and AP-1 pathways 37.
SLFN Proteins Biological Functions. SLFN and mSLFN genes are highly present in immune
cells and their importance has been remarkable because of their role in immune responses, control
of cell cycle proliferation as well as regulation of viral replication 38. Particularly, the expression
of SLFN1 inhibits cyclin D1 function in NIH3T2T murine fibroblasts, resulting in cell cycle arrest
prior to the G1/S transition39. Cyclin D1 protein is crucial for the G1/S stage, and the
overstimulation of this protein in SLFN1 expressing cells showed an increase in cell growth.
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Therefore, cyclin D1 is one of the main targets of SLFN1 protein.mSLFN2 contributes to cell
growth, differentiation and immune response. mSLFN2 mutations in mice increases susceptibility
to bacterial and viral infections40. Silencing of SLFN2 decreases activation of c-Jun ad expression
of NFATc1 results in decreased osteoclastogenesis. mSLFN proteins are also capable to modulate
differentiation of T cells and macrophages.33 Expression of mSLFN3 has been found in CD 4 and
CD25 circulating T cells, however activation and proliferation of them results in mRNA
downregulation. Moreover, it been demonstrated that mSLFN3 exerts a function in intestinal
development and maturation.

41.

Ectopic expression of mSLFN3 results in anti-proliferative

properties, by decreasing cell proliferation as well as decreased levels of proliferating cell nuclear
antigen.32 Sensitization of cells to chemotherapy resistance is another characteristic of mSLFN3.
Ectopic expression of mSLFN3 inhibits characteristics of cancer stem cells. In regards to functions
of human SLFNs, research demonstrates that SLFN5 possess negative regulatory effects on
anchorage- independent melanoma cells in collagen35, whereas SLFN11 appears to have anti-viral
effects, by impairing the production of retroviruses. Moreover, SLFN11 also sensitizes malignant
cells to topoisomerase inhibitors and DNA- damaging agents 42 43.
SLFN proteins are involved with virus replication, acting on open reading frames to suppress viral
replication44.One of the typical targets of SLFN proteins are HIV and camel pox virus45,46. In
addition, research demonstrates that mSLFN14 impairs Influenza A and Varicella Zoster virus by
affecting nuclear trafficking of nucleoproteins47.
In December 2019, a large number of cases reported as “pneumonia of unknow etiology” were
reported in Wuhan, China. This led to an intensive investigation program, which attributed those
cases to a novel virus belonging to the Coronavirus family. Viruses on this family are known for
their potential to develop respiratory disease outbreaks, causing illness ranging from common
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colds to MERS and SARS48. Literature postulates the probability of origin of this virus from bats,
until they were able to infect other mammalian hosts before infecting humans. Transmission of
this pathogen occurs from respiratory droplets and exposure to elevated aerosol concentrations in
closed spaces. In addition, the virus can be transmitted human- to- human by asymptomatic
individuals, and therefore isolation has been recommended to counteract this epidemic.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a positive sense singlestranded [(+)ss] RNA virus of around 60-140 nm. Its viral structure presents a round or elliptic
from with a crown-like appearance due to the presence of glycoproteins on its envelope which
guides the virus to the host receptors49. Enclosed by nucleocapsid proteins is its genome, consisting
of 29,891 nucleotides. At least 14 open reading frames (ORFs) have been identified, coding for
viral proteins50. A single ORF at the end of its genome codes for a polyprotein that is subsequently
cleaved into 16 non-structural proteins, thus allowing for the formation of the replicasetranscriptase complex49. Until now, there is no specific treatment or vaccine for SARS-CoV-2.
However, previous work and publications from our laboratory demonstrates that SLFN11 is able
to impair (+)ssRNA viruses, such as West Nile, dengue and zika viruses 4. In addition, SLFN11
impairs HIV-1 as I have demonstrated in this work, exploiting the fact that HIV-1 genome is codon
usage biased. Importantly, SARS-CoV-2 is both (+)ssRNA and the genome is codon usage biased,
therefore its is possible that SLFN11 could impair SARS-CoV-2 infection, a current active
research in my laboratory.
Effects of SLFN proteins on HIV-1 infection. Viral infections induce type I interferons, a group
of signaling proteins known for their potent anti-viral activity. Schlafen genes are a subset of early
response genes, induced also by pathogens via the interferon regulatory factor 3 pathway 37. A
member of the Schlafen family, SLNFN11 impairs HIV-1 protein expression2. Research
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demonstrates that SLFN11 does not affect integration, transcription or reverse transcription of
HIV, but it rather acts in the late stage of the infection cycle by inhibiting the expression of viral
proteins of the codon-biased HIV-1 genome. 2. SLFN11 binds to tRNA, thus counteracting
upregulation of the tRNA pool elicited by HIV to subsequently inhibit viral protein synthesis 2.
Recently, another member of the schlafen family, SLFN13 has been proposed as a tRNA/rRNA
targeting endoribonuclease, which possesses a unique U-pillow- shaped structure in its N- domain,
which enables base-paired cleavage of RNAs3. Cleavage takes place at the acceptor steam of the
substrate tRNA, by removing 11 nucleotides at the 3′ terminus 3. Nine residues are implicated in
the nucleolytic activity of SLFN13, and 8 of them are conserved in SLFN11, which suggest that
the antiviral mechanism of SLFN11 involves tRNA nucleolytic activity. In addition, it was
demonstrated that this enzymatic activity is essential for SLFN13 to restrict HIV-1 protein
expression.
This thesis focuses on the study of mSLFN proteins and the study of the mechanisms implicated
in their anti-viral activity.
Significance.
Although effective antiretroviral drugs have helped to slow the progression of new HIV-1
infections and control the multiplication of HIV-1 in infected patients preventing AIDS
development, still HIV-1 infection is incurable and patients require treatment for life 51. The main
obstacle to cure HIV-1 infection is that the current treatment does not eliminate a reservoir of
latently infected cells. These are long-lived cells in which no viral proteins are expressed and
therefore these cells can neither be eliminated by the immune system nor viral cytopathic effects.
Two different strategies are envisioned for a cure. One strategy is based in the so called “Berlin
Patient”, the only HIV-1 patient cured. This patient received a successful allogenic bone marrow
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transplant of cells carrying a mutation in one of the HIV-1 co-receptors and therefore naturally
resistant to HIV-1. This case sparkled interest in the development of ex vivo modified patient cells
resistant to HIV-1 for autologous transplant by engineering the stable overexpression of HIV-1
restriction factors. The second cure strategy intended to trigger latency reactivation leading to
death of the latently infected cells by the toxicity of viral replication or immune clearance.
The anti-HIV-1 mechanism of SLFN11 has potential use in both cure strategies. Patient cells
constitutively overexpressing SLFN11 could restrict HIV-1 infection. This is particularly
important considering that type 1 IFN is the main induction mechanism of SLFN11 during viral
infections and HIV-1 efficiently impair secretion and activity of this cytokine. In addition,
limitation of the SLFN11 anti-viral activity could eliminate post-transcriptional barriers during
latency reactivation.
However, exploiting the SLFN11 anti-HIV-1 activity requires a deeper understanding of the
importance of this innate immune restriction pathway in cells relevant to HIV-1 infection in vivo
and of the SLFN11 mechanism of action. My work in specific aims 1 and 2, respectively, will
contribute to eliminate these gaps in knowledge.
Specific Aims. This thesis focuses on the evaluation of the anti-viral activity of the group III mouse
SLFNs. Specifically, mSLFN5, mSLFN8, mSLFN10 and mSLFN14 will be tested against HIV-1.
Our laboratory has provided evidence that SLFN11 impairs replication of West Nile, Dengue and
Zika Virus and confirmed the anti-HIV-1 effect previously reported. However, the structural
determinants of the anti-HIV-1 activity are ill-defined. To uncover this, we have determined the
anti-HIV-1 activity of a panel of mSLFN proteins that have some degree of homology at the protein
level with SLFN11. To this end, we have completed the following specific aims:

11

Specific Aim 1. To generate A172 KD cell lines stably expressing different mSLFN proteins
A172 cells are permissive to single-round HIV-1 infection. Our laboratory previously
demonstrated that knockdown of SLFN11 in these cells increases their susceptibility to HIV-1
infection that is reduced upon re-expression of this protein. Therefore, A172 KD cells are a suitable
reporter system to evaluate the anti-HIV-1 activity of mSLFN proteins.
Specific Aim 2. To determine the anti-HIV-1 activity of mSLFN proteins
For this specific aim we evaluated HIV-1 infection susceptibility of the mSLFN generated cell
lines. We took advantage of an HIV-1-derived virus that express from the viral promoter Gag and
firefly luciferase. In contrast to firefly luciferase, Gag exhibits a marked codon bias therefore it
was expected that Gag but not luciferase expression will be affected by SLFN11 like mSLFN. Gag
was determined by measuring HIV-1 p24 by enzyme-linked immunosorbent assay and luciferase
by a luminescence-based enzymatic assay.

12

MATERIALS AND METHODS
Cell lines and viruses. HEK293T, SupT1, THP-1 U87 and A172 cells were obtained from the
American Type Culture Collection (Manassas, VA). A172 and HEK293T cell lines were
maintained in modified Eagle’s medium (DMEM); THP-1 and SupT1 cells were maintained in
RPMI 1640. Culture media were supplemented with 10% fetal bovine serum (FBS), 1% penicillin
and streptomycin, 1% nonessential amino acids (NEAA), and 1% sodium pyruvate. U87 Cells
were maintained in DMEM and supplemented with FBS 15% and 300 µg/ml G418.
(Hluc), a replication- defective HIV-1 reporter virus was used. This virus expresses long terminal
repeat (LTR)-driven luciferase from the negative factor (NEF) slot and contains a large deletion
in envelope (ENV)52. Generation of Hluc virus was performed by calcium phosphate transfection
of the corresponding HIV-1 expression plasmid d (pHluc; 15 μg) and the VSV glycoprotein G
(VSV-G)-encoding plasmid pMD.G (5 μg) into HEK293T cells, as described previously52.
Concentration of viruses was performed by using Lenti- X concentrator (Takara Bio). In brief,
Supernatant from lentiviral packing cells was briefly centrifuged at 500 x g for 10 minutes, and
filtered through a 0.45 μm filter (ThermoScientific). Clarified supernatant was transferred to a
sterile container and combined with 1 volume of lenti-X concentrator with 3 volumes of clarified
supernatant and mixture was incubated 4°C for 30 minutes. Then, sample was centrifuged at 1,500
x g for 45 minutes at 4°C. Finally, supernatant was removed and the pellet was re-suspended
1/100th of the original volume using complete DMEM. Samples were stored at –80°C for further
use.
All work involving HIV-1, was performed in a BSL-2 laboratory in accordance with biosafety
practices described in The University of Texas at El Paso Biological Safety Manual.
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Single-round infectivity assay. A172-derived cells were seeded onto 24-well plates (1 x 10 ^5
cells/well) and allowed to grow overnight. The next day, cells were infected with Hluc, and 24 h
later, the cells were extensively washed with basal DMEM to remove the input virus. Four days
later, the cell culture supernatant was collected for HIV-1 p24 quantification, and cell lysates were
prepared in a buffer containing 1% Triton X-100 for luciferase activity quantification (BrightGlow luciferase assay system; Promega), according to the manufacturer’s instructions. Luciferase
activity was determined in samples using a microplate luminometer reader (Luminoskan Ascent;
Thermo Scientific). Luciferase and HIV-1 p24 samples were derived from at least three
independent infections.
HIV-1 replication. 10^5 SUPT1- or U87-derived cells lines were incubated overnight with HIV1 strain NL4-3 (25ng of p24) in 0.5 mls of culture medium. Subsequently, the input virus was
removed by extensively washing and cells were placed in 4 mls of culture medium. After day 4
post-infection supernatant was collected every other day until cells die due to cytopathic effects.
Then, HIV-1 p24 was measured by ELISA in the cell supernatants collected.
Immunoblotting. Full procedures for protein detection by immunoblotting have been described
previously53.Briefly, Cellular lysates were obtained by lysing cells with 2 X Laemmli buffer and
boiling for 10 min. Cell lysates were resolved by SDS-PAGE and transferred overnight onto
polyvinylidene difluoride (PDVF) membranes at 100 mA at 4°C. Membranes were blocked in
Tris-buffered saline (TBS) containing 10% milk for 1 h and then incubated with the corresponding
primary antibody diluted in TBS–5% milk– 0.05% Tween 20 (antibody dilution buffer). Fulllength SLFN 5, 8,9,10 and 14 were detected with anti-Flag antibody (Sigma- aldrich) (1/500). In
addition, anti-SLFN11 antibody D-2 (Santa Cruz Biotechnology) (1/500) was used to detect
SLFN11. Alpha-Tubulin was detected as a loading control with antibody from clone B-5-1-2
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(Sigma) (1/4,000). Membranes were incubated overnight at 4°C with primary antibodies, whereas
anti- -tubulin monoclonal antibody (MAb) was incubated for 30 min at 25°C. Primary antibodybound membranes were washed in TBS– 0.1% Tween 20, and bound antibodies were detected
with goat anti-mouse IgG-horseradish peroxidase (HRP) (Sigma) (1/2,000, followed by
chemiluinescence detection. Densitometry of selected bands was quantified based on their relative
intensities using Image Studio software (Li-Cor, Lincoln, NE).
Plasmids. Plasmids needed for the generation of HIV-1 derived viral vectors were obtained from
the Eric Poeschla laboratory (Mayo Clinic, Rochester, MN) 53. These lentiviral vectors were used
to express mSLFN5, mSLFN8, mSLFN10 and mSLFN14 proteins. They were generated with
packaging plasmid pCMVΔR8.91, a transfer plasmid derived from pTRIP (described below), and
the envelope plasmid pMD.G encoding VSVG.
mSLFN expression plasmids.
mSLFN5, mSLFN8, mSLFN10 and mSLFN14 pCMV6-Entry expression plasmids were purchase
from OriGene. These mSLFN cDNAs were subcloned into an HIV-1-derived vector (TRIP-IRESP) by PCR using the Phusion- Site directed mutagenesis kit ( Thermo Fisher Scientific).
Production of lentiviral vectors. Assembly of the pTRIP derived transfer plasmids was
performed by using Nebuilder HiFi DNA Assembly Master Mix kit (New England Biolabs).
Entire procedures for transfection and production of lentiviral vectors have been described
previously52-54. In brief, HEK293T cells were calcium-phosphate transfected with the
corresponding transfer plasmid derived from pTRIP (15μg), packaging plasmid pCMVΔR8.91
(15μg), and VSV-G envelope expression plasmid pMD.G (5 μg).72 h post transfection viral
supernatants were harvested and concentrated with Lenti-X concentrator (Takara Bio) following
manufacturer protocol.
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Expression of full-length mSLFN proteins in SLFN11-deficient cell lines.A172 cells were
manipulated by to express mSLFN5 protein by plating 1.3 x 10 ^6 cells in a T 75 flask. Followed
by transfection with PEI 1 X. 48 hours post transfection cells were selected in the presence of
geneticin. In addition, A172 KD cells were engineered to express mSLFN8, mSLFN10 and
mSLFN14 proteins by transduction with lentiviral vectors expressing each of the previously
mentioned proteins and the puromycin resistance gene. Briefly, viral vectors were produced in n
HEK293T cells by transfection with the pTRIP-IRES-P- Slfn transfer plasmid expressing fulllength SLFN proteins (15 μg) and the packaging and envelope expression plasmids described
above Viral supernatants were concentrated with Lenti-X (Takara Bio).A172 KD cells were seeded
in a 24-well plate (1 x 10 ^5 cells/well in 400 uL- total volume) and transduced the next day with
different M.O.I’s. After three days transduced cells were selected in the presence of puromycin (3
μg/ml) for A172 KD cells. Surviving cells were expanded as necessary.
HIV-1 p24 ELISA. HIV-1 p24 in the supernatants of the infected cells was measured by ELISA.
(ZeptoMetrix Corporation). ELISAs were performed according to the manufacturer’s instructions.
Statistical analysis. Statistical significance of data represented in bar graphs was determined using
one-way ANOVA with Tukey HSD test, and in data represented as replication curves with multiple
experimental points was determined by two-way ANOVA with Bonferroni post-hoc test.
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RESULTS
SLFN11 impairs HIV-1 replication. SLFN11 knockdown (KD) was reported to enhance HIV-1
replication in the human CD4+ T cell line CEM55 . However, since this original Nature report in
201255, no other publication has indicated an effect of SLFN11 on HIV-1 replication sparkling
general doubts on the relevance of the anti-HIV-1 activity of this protein in the HIV-1 research
community. In order to clarify this important issue we evaluated the effect of SLFN11 on HIV-1
replication in the human CD4+ T cell line SUP-T1 and in the human astrocytoma-derived U87
CD4+CXCR4+ reporter cell line. The latter although is not a target for HIV-1 in vivo has been
widely used in HIV-1 research. These cells were stably transfected with either a shRNA against a
scrambled sequence or SLFN11. Expression of SLFN11 was evaluated in these cells by
immunoblotting with a specific antibody and as a loading control alpha tubulin was detected in
these experiments. Levels of SLFN11 in U87 CD4+CXCR4+ shRNA cell line decreased
dramatically (Fig. 2B), whereas in SUP-T1 some expression is still appreciated (Fig. 2A).

Subsequently, these cells were infected with HIV-1 wild type, the input virus removed, and after
day 4 post-infection supernatant was collected every other day until cells die due to cytopathic
effects. Then, HIV-1 p24 was measured by ELISA in the cell supernatants collected. U87
CD4+CXCR4 and SUP-T1 SCR cell lines demonstrated lower p24 levels in comparison to the
17

corresponding SLFN11 KD cell lines (Fig. 3). Importantly the differences between each pair of
control and KD cell lines in SLFN11 directly correlated with their differences in p24 (Fig. 3).
These results indicated that SLFN11 impairs HIV-1 replication in relevant cell lines.

SLFN11 impairs HIV-1 infection in human myeloid cells. In further support of a role of
SLFN11 in HIV-1 infection our laboratory have demonstrated that SLFN11 KD enhances HIV-1
single-round infection, in the human A172 (glioblastoma) and HEK293 cells 4. For this thesis I
repeated the experiments with A172-derived cell lines. Then, A172-derived cells expressing an
shRNA with an shRNA against SLFN11 (KD) or KD cells re-expressing SLFN11 (BC) were
infected with an HIV-1-derived reporter virus that lacks Env and has replaced Nef with the
luciferase cDNA (HΔEluc). This virus can undergo only one round of infection. The reporter gene
luciferase was determined in cell lysates and p24 was measured in the supernatants of infected
cells by ELISA at day 4 post-infection. It has been reported that SLFN11 affect selectively the
translation of codon biased messengers3,55, then we normalized HIV-1 p24 to HIV-1 luciferase
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levels to exclude any effect of the genetic manipulation introduced in the target cell lines used in
these experiments that could affect the steps of the viral life cycle prior to viral-encoded translation.
This strategy allows focusing only on the effect of the genetic perturbations on HIV-1 protein
translation. Using this model we observed that SLFN11 KD cells produced close to six fold more
p24 than SCR cells and that these differences were substantially removed when SLFN11 was reexpressed in the KD cells (BC cells) (Fig. 4).

These findings are important because the work previously reported in Nature55 was conducted in
an experimental model that do not include viral infection. Instead this group cotransfected in
HEK293T cells both a SLFN11 and an HIV-1 expression plasmids in the absence of infection. We
will refer here to this model as co-transfection model. However, an important caveat of the
published4,55 and figure 3 data is the use of cells that are not representative of cell types infected
by
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HIV-1 in vivo, i.e. A172, HEK 293, and HEK 293T cells. Therefore to verify further the relevance
of the anti-HIV-1 activity of SLFN11 in a relevant cell type we chose THP-1 cells. This model is
relevant since HIV-1 in vivo infect CD4+ T cells and macrophages, and THP-1 are myeloid cells
that resemble macrophages/monocytes. In addition we (Fig. 2A) and others55 have demonstrated
a role of SLFN11 in CD4+ T cells but myeloid cells have not been evaluated yet. Then, THP-1
cells were transduced by spin-inoculation with two different retroviral vectors containing a
puromycin resistant cassette. One of this vectors expressed SLFN11, while the control or empty
vector did not express SLFN11. After transduction, cells were selected in the presence of
puromycin and expression of SLFN11 was analyzed by immunoblotting (Fig. 5). Tubulin was also
detected in the same immunoblot membranes to verify equal loading. These cells were infected
with HΔEluc and analyzed as described above by normalizing HIV-1 p24 levels to luciferase
activity. Using this model we observed that overexpression of SLFN11 impairs HΔEluc p24
production (Fig. 6).
To further verify the role of SLFN11 in these cells, we also transduced THP-1 cells with a retroviral
vector expressing an SLFN11-specific shRNA. As expected, these cells expressed lower levels of
SLFN11 as detected by immunoblot analysis (Fig. 7).
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Infection of these and control THP-1 cells with HΔEluc was tracked as described above.
Importantly, HIV-1 p24 production normalized to luciferase values was higher in the SLFN11 KD
cells (Fig. 8), further demonstrating the anti-HIV-1 activity of this host protein.
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tRNase activity of SLFN11 is essential to impair HIV-1 infection. It has been proposed that the
catalytic activity of SLFN11 is required for the anti-HIV-1 activity55. However, as mentioned
above, these data were obtained in the HEK293T cotransfection model in the absence of infection.
Therefore, in order to clarify the role of tRNase in the anti-HIV-1 activity of SLFN11 in a more
relevant experimental model, we determined the effect of SLFN11 tRNase-dead mutant on
HΔEluc infection in A172 KD. This is a good for this experimental question as we demonstrated
above (Fig. 4). Then, this mutant was generated by substituting the catalytic residues E209 and
E214

3

with A and A172 KD cells were transduced with a retrovirus expressing this mutant

genetically linked to the puromycin resistance cassette. The SLFN11 catalytic mutant was robustly
expressed in A172KD cells as shown by immunoblot in figure 9. A172 KD cells and these cells
expressing SLFN11 wild type or catalytic mutant were infected with HΔEluc and infection was
monitored as described above. HIV-1 p24-luciferase normalized data in figure 10 demonstrated
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that SLFN11 catalytic mutant failed to impair HIV-1 p24 production. Therefore, our results also
confirmed the relevance of tRNase in the anti-HIV-1 activity of SLFN11.

tRNase-dependent and -independent mechanisms mediate the anti-HIV-1 activity of murine
SLFN proteins. To further determine the role of tRNase activity on the anti-HIV-1 activity of
SLFN proteins we also evaluated the anti-HIV-1 activity of murine (m) SLFNs belonging to the
group III of this family. Importantly, SLFN11 and 13 that has been reported to impair HIV-1
infection 3,55 and both belong to this same group of the SLFN family. The anti-HIV-1 activity of
SLFN11 resides in the N-terminal portion of this molecule55. Comparison of the amino acid
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sequence of these humans and mSLFN proteins indicate between 53-69% of homology (Table 1).
Importantly, analysis of the conservation of the catalytic triad amount these SLFNs (Table 2)
predict that mSLFN 5 and 10 will lack tRNase activity. This prediction is supported by the fact
that human SLFN5 that only lacks one of the three catalytic residues does not have tRNase activity
and does not impair HIV-1 p24 expression55.

However, mSLFN8, 9, and 14 are expected (Table 2) or have been demonstrated (SLFN13)3 to
have tRNase activity. mSLFN9 and 8 arrived by gene duplication and has 85% homology in their
N-terminus. Therefore, they are expected to be functionally equivalent, based on this fact we
decided to explore the function of mSLFN8 variant 2 that represent only the n-terminus of
mSLFN8 rather than of the full-length variant 1. This strategy will also allow us to define if for
the mSLFN proteins the N-terminus was sufficient to mediate their anti-HIV-1 function.
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Then, we generated A172 KD-derived cell lines expressing mSLFN5, mSLFN8, mSLFN10 and
mSLFN14 by transducing these cells with lentiviral vectors expressing these flag-tagged mSLFN
proteins and a puromycin resistance cassette. Transduced cells were expanded as necessary and a
cell lysates were obtained from each of the established cell lines. Then, mSLFN protein expression
was determined by immunoblotting using an anti-flag antibody, and alpha tubulin was detected as
a loading control (Fig. 11).

Lower expression of mSLFN5, mSLFN9 and mSLFN14 than of mSLFN10 was achieved. These
cell lines were infected with HΔEluc and 4 days post-infection luciferase (Fig. 12) and p24 values
were measured and further normalized to luciferase levels (Fig. 13).
As expected, mSLFN8, 9, and 14 that conserve the tRNase catalytic residues impaired HIV-1 p24
production but did not modify luciferase levels (Fig. 12 and 13) indirectly supporting further the
role of tRNase in the anti-HIV-1 activity of these proteins Moreover, mSLFN8 variant 2 that
represents the N-terminus of this protein, were the catalytic triad is located, was sufficient to impair
HIV-1.
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However, mSLFN5, which naturally lacks two of the catalytic residues, and mSLFN10 that lack
one on the critical residues (table 2) potently inhibited HIV-1 p24 production in a similar fashion
than SLFN11. A potential explanation for the findings with mSLFN5 or mSLFN10 is that
endogenous SLFN11 inadvertently was re-express in the A172KD cells during the generation of
these cell lines. We were not able to detect endogenous SLFN11 in any of the cell lines expressing
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the murine proteins but SLFN11 levels below the detection level of our immunoblots could be
functional, for example notice that low levels of mSLFN9 and 14 (Fig. 11) potently impair HIV1 p24 production (Fig. 13). Therefore, to exclude this possibility we expressed mSLFN5 in A172
SCR cells that express wild type levels of SLFN11 (Fig. 11) and determined the effect ofmSLFN5
overexpression on HIV-1 p24 production. These cells were infected with HΔEluc and evaluated
as described above. Importantly, mSLFN5 potently inhibit HIV-1 p24 production in the presence
of wild type SLFN11 (Fig. 14).
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DISCUSSION
Our data confirmed the relevance of SLFN11 in HIV infection in cells that are relevant to the HIV1pathogenesis. The role of SLFN11 in HIV-1 infection is a topic in discussion in the HIV-1
research community. The first report of this relevant mechanism appeared in Nature in 2012 2 and
not until 20194 was any original report on this activity. Last year report was published in Journal
of Virology by our lab and confirmed the original observations in a different in vitro HIV-1
infection model. However, these observations were made in cell types that were not relevant to
HIV-1 infection in vivo keeping the lack of interest in the field. Therefore, one of my specific aims
was to determine the role of SLFN11 in HIV-1 infection CD4+ and myeloid cells, the main targets
of HIV-1 in vivo. My data confirmed that both over expression or downregulation of SLFN11
impair HIV-1 infection of wild type and single-round infection HIV-1. These findings are expected
to eliminate doubts in the HIV- research community on the role of SLFN11 in HIV-1 infection.
We also have advanced our understanding of the anti-HIV-1 mechanism of action of SLFN
proteins. We demonstrated that mSLFN proteins conserve the ability of human SLFN11 to impair
HIV-1 p24 production acting at a post-transcriptional step of the virus life cycle. We also
confirmed in a relevant in vitro HIV-1 infection model that in SLFN11 the tRNase activity is
necessary. These findings also provide significance to the role of SLFN11 in HIV-1 infection since
the Nature 2012 mechanistic studies were made in non-infected cells. However, more relevantly
we have demonstrated that mSLFN proteins lacking the tRNase catalytic residues exhibit a potent
anti-HIV-1 activity indicating the existence of tRNase-dependent and -independent mechanisms.
Importantly both mechanisms affect HIV-1 at a post-transcriptional level. We speculate that HIV1 has evolved an strategy to evade the tRNAse-independent mechanism present in SLFN11, but
fails to counteract the murine SLFNs. HIV-1 has also evolved a mechanism to escape the tRNase-
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dependent anti-viral activity of SLFNs. The mechanism consists in maintaining the early viral
proteins encoded in open reading frames with low codon bias. This is the case of Tat, Rev, and
Nef. Therefore production of these proteins is less restricted by SLFN11; once Tat is produced
viral transcription is significantly amplified overcoming the effects of SLFN11 on translation of
the codon biased viral open reading frames. Similarly Rev contribute to a more efficiently export
of these viral mRNAs guaranteeing that the translational machinery is flooded with viral
messengers. The role of Nef in this viral strategy that we postulate is not known yet. However, Nef
is a multifunctional protein that drastically affect multiple signaling pathways in the cell and that
is essential in vivo. Perhaps these potentially SLFN11-indpendent early functions have fueled the
codon adaption of Nef. We postulate that drugs inhibiting these viral proteins (not available yet)
will act at lower doses in cells expressing higher levels of SLFN11. Similarly HIV-1 carrying
mutations that diminish the activity of these proteins will be more sensitive to the inhibitory effect
of SLFN11. Therefore, we envision that, despite of HIV-1 escapes SLFN11 restriction, its antiHIV-1 activity could be enhanced by conditions that decrease the levels of functional HIV-1 early
proteins.
Conclusions.
Our data evidenced that SLFN11 impairs HIV-1 infection in CD4+ and myeloid cells, the main
targets of HIV-1 in vivo, by reducing HIV-1 p24 production in a tRNase-dependent manner. These
results highlight the relevance of this innate immune anti-HIV-1 mechanism.
In addition, we found that mSLFN proteins lacking tRNase catalytic activity are capable of
impairing HIV-1 infection at a pot-transcriptional step of the viral life cycle, illustrating the
complexity of the anti-HIV-1 activity of the SLFN proteins at a mechanistic level.
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